首页> 美国卫生研究院文献>Clinics in Colon and Rectal Surgery >Ulcerative Colitis: Pros and Cons of Medical Management of Ulcerative Colitis
【2h】

Ulcerative Colitis: Pros and Cons of Medical Management of Ulcerative Colitis

机译:溃疡性结肠炎:溃疡性结肠炎医疗管理的利弊

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ulcerative colitis (UC) is a chronic inflammatory disease characterized by diffuse mucosal inflammation limited to the colon and rectum. Although a complete medical cure may not be possible, UC can be treated with medications that induce and maintain remission. The medical management of this disease continues to evolve with a goal to avoid colectomy and ultimately alter the natural history of UC. Emergence of antitumor necrosis factor-α (TNF-α) agents has expanded the medical armamentarium. 5-Aminosalicylates continue to be used in mild to moderate UC and corticosteroids are mainly used for induction of remission with immunomodulators (6-mercaptopurine/azathiopurine/methotrexate) being applied as steroid-sparing agents for maintenance therapy. Infliximab has been approved by the U.S. Food and Drug Administration and used in the treatment of moderate to severe UC; nevertheless, its use may be associated with significant adverse effects and have a negative impact on the postoperative course should the patients undergo restorative proctocolectomy. In addition, there is always a concern about patients' compliance to medical therapy, cost of medications, and risk for UC-associated dysplasia. The authors discuss the pros and cons of medications used in the treatment of UC.
机译:溃疡性结肠炎(UC)是一种慢性炎症性疾病,其特征在于局限于结肠和直肠的弥漫性粘膜炎症。尽管不可能完全治愈药物,但可以用诱导并维持缓解的药物治疗UC。为了避免结肠切除术并最终改变UC的自然病史,该疾病的医疗管理不断发展。抗肿瘤坏死因子-α(TNF-α)药物的出现扩大了医疗设备。 5-氨基水杨酸酯继续用于轻度至中度的UC,皮质类固醇主要用于诱导缓解,免疫调节剂(6-巯基嘌呤/硫唑嘌呤/甲氨蝶呤)被用作维持治疗的类固醇制剂。英夫利昔单抗已获得美国食品药品监督管理局的批准,可用于中重度UC的治疗。但是,如果患者进行了恢复性结肠直肠癌切除术,其使用可能会带来严重的不良反应,并对术后病程产生负面影响。此外,人们始终担心患者对药物治疗的依从性,药物成本以及与UC相关的发育异常的风险。作者讨论了用于UC治疗的药物的优缺点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号